IND submission is a major milestone in the life of your drug. We can provide all supporting analytical data to help ensure a smooth application process.
We have the expertise, flexibility, and resources to provide a full range of pharmaceutical API custom development services at every stage of the lifecycle.
We can provide lab-, kilo- and pilot-scale manufacturing for preclinical studies and all phases of clinical trials, supplying milligram to kilogram quantities.
Cambrex brings more than 40 years of generic API manufacturing experience to its pharmaceutical partners. From our sites in Italy, Sweden, and the USA, we are a leading global supplier of generic APIs.
Drug substance tech transfer sounds so simple on the surface, but it’s a complex activity carrying a number of technical, regulatory, and quality risks.
At Snapdragon Chemistry, now part of Cambrex, our chemists specialize in creating custom solutions and technologies to take on your toughest process development and production challenges. This includes expertise in designing and building reactors that enable seamless technology transfer as a process scales up for commercial manufacturing.
At Cambrex, we provide a range of technologies equipped to solve your API manufacturing challenges, and we are flexible enough to handle the most complex molecules.
You can rely on our extensive portfolio of analytical development solutions and testing services to rapidly advance your molecule for the greatest chance of success.
We’re solid state chemistry experts who can deliver timely, phase-appropriate solutions to optimize the physical stability of your API, develop a more bioavailable formulation or overcome other challenges.
Cambrex’s experienced analysts are well-equipped to ensure microbial testing is of the highest quality for our customers and delivered with a quick and reliable turnaround.
Cambrex and Q1 Scientific’s stability storage and sample management capabilities provide a variety of pharmaceutical storage conditions, with walk-in and reach-in chambers that meet all ICH Q1A requirements.
Cambrex offers extensive development services tailored to meet your drug product needs in early development. From pre-formulation to Phase II, we ensure your products are developed with speed, flexibility, and quality in mind.
Whether you need rapid development, flexible manufacturing solutions, or high-quality production, Cambrex is your trusted partner for advancing your drug product from concept to the clinic.
Cambrex is here to support you in early-phase development. Our development experts apply their ingenuity and skill to address your unique challenges.
Our teams of creative problem-solvers work closely with you to accelerate drug development timelines, optimize processes, and meet regulatory requirements.
We understand that the commercial phase of drug development can be challenging, especially when it comes to manufacturing at scale and meeting changing market demands.
Cambrex is a leading global supplier of more than 70 generic APIs, as well as intermediates and derivatives.
Innovation across the pharmaceutical industry has given way to a wide range of novel modalities, opening up new possibilities in patient care. Despite the industry’s evolving landscape, the success rate for drug candidates during early development continues to sit at only 10%.¹
The good news, though, is that when you understand the pitfalls that can impede early development, the associated risks can be effectively managed, ultimately driving your program and your organization toward long-term commercial success.
In a recent roundtable discussion, a panel of product development experts with diverse perspectives examined the blind spots that can plague an early development strategy, as well as which considerations must be accounted for when navigating the path toward an IND submission.
Download this whitepaper to read more.
Thank you for your interest in our content.
Pharmaceutical and biotech companies often face a pivotal decision: should they manage certain operations internally or partner with a trusted external provider? In this webinar, we explain how outsourcing stability storage and testing offers a strategic advantage, enabling pharmaceutical and medical device companies to optimize their stability programs and stay competitive in the global market.
In our latest whitepaper, we dive deeper into the strategic benefits of outsourcing stability storage, provide you with a comprehensive guide on how to select the right partner for your needs, and highlight case studies that showcase real-world examples of pharmaceutical companies that have successfully outsourced stability storage and reaped the benefits.
Performing stability storage in-house can entail significant costs and risks for pharmaceutical and medical device companies, including capital and operational expenditures, compliance risks, and opportunity costs due to capacity constraints. In our recent infographic, we highlight the various costs and risks associated with in-house stability storage.